Arabinosyltransferase C Mediates Multiple Drugs Intrinsic Resistance by Altering Cell Envelope Permeability in Mycobacterium abscessus
暂无分享,去创建一个
Guoliang Zhang | G. Cook | Sheng Zeng | Tianyu Zhang | Buchang Zhang | H. A. Hameed | C. Chhotaray | Xirong Tian | H. Ge | Yongping Lin | Zhili Lu | D. A. Maslov | Wei-Ting Yu | Shuai Wang | Cuiting Fang | Yamin Gao | Lingmin Guo | Jingran Zhang | N. Zhong | Buhari Yusuf | Jiacong Peng | X. Cai | M. Alam
[1] D. Wei,et al. Improving the biotransformation of phytosterols to 9α-hydroxy-4-androstene-3,17-dione by deleting embC associated with the assembly of cell envelope in Mycobacterium neoaurum. , 2020, Journal of biotechnology.
[2] G. Besra,et al. Structures of cell wall arabinosyltransferases with the anti-tuberculosis drug ethambutol , 2020, Science.
[3] L. Kremer,et al. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus , 2020, Nature Reviews Microbiology.
[4] Guoliang Zhang,et al. Assessment of Clofazimine and TB47 Combination Activity against Mycobacterium abscessus Using a Bioluminescent Approach , 2019, Antimicrobial Agents and Chemotherapy.
[5] S. Shin,et al. Rifabutin Is Active against Mycobacterium abscessus in Mice , 2019, Antimicrobial Agents and Chemotherapy.
[6] L. Chiarelli,et al. Mycobacterium abscessus, an Emerging and Worrisome Pathogen among Cystic Fibrosis Patients , 2019, International journal of molecular sciences.
[7] Md. Mahmudul Islam,et al. Comparative Analysis of Whole-Genome and Methylome Profiles of a Smooth and a Rough Mycobacterium abscessus Clinical Strain , 2019, G3: Genes, Genomes, Genetics.
[8] G. Lamichhane,et al. Synergistic Efficacy of β-Lactam Combinations against Mycobacterium abscessus Pulmonary Infection in Mice , 2019, Antimicrobial Agents and Chemotherapy.
[9] Tianyu Zhang,et al. The compound TB47 is highly bactericidal against Mycobacterium ulcerans in a Buruli ulcer mouse model , 2019, Nature Communications.
[10] P. Sander,et al. The Role of Antibiotic-Target-Modifying and Antibiotic-Modifying Enzymes in Mycobacterium abscessus Drug Resistance , 2018, Front. Microbiol..
[11] K. Becker,et al. Lipoprotein Glycosylation by Protein-O-Mannosyltransferase (MAB_1122c) Contributes to Low Cell Envelope Permeability and Antibiotic Resistance of Mycobacterium abscessus , 2017, Front. Microbiol..
[12] L. Kremer,et al. Bedaquiline Inhibits the ATP Synthase in Mycobacterium abscessus and Is Effective in Infected Zebrafish , 2017, Antimicrobial Agents and Chemotherapy.
[13] H. Kwon,et al. Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessus , 2017, Antimicrobial Agents and Chemotherapy.
[14] G. Lamichhane,et al. Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus. , 2017, Future Microbiology.
[15] E. Böttger,et al. Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591 , 2017, The Journal of antimicrobial chemotherapy.
[16] Mithila Rajagopal,et al. Multidrug Intrinsic Resistance Factors in Staphylococcus aureus Identified by Profiling Fitness within High-Diversity Transposon Libraries , 2016, mBio.
[17] Y. Liu,et al. Identification of Lysine Acetylation in Mycobacterium abscessus Using LC-MS/MS after Immunoprecipitation. , 2016, Journal of proteome research.
[18] Y. Hamada,et al. Antibacterial Efficacy of Eravacycline In Vivo against Gram-Positive and Gram-Negative Organisms , 2016, Antimicrobial Agents and Chemotherapy.
[19] G. Besra,et al. Assembly of the Mycobacterial Cell Wall. , 2015, Annual review of microbiology.
[20] Po-Ren Hsueh,et al. Mycobacterium abscessus Complex Infections in Humans , 2015, Emerging infectious diseases.
[21] A. Diacon,et al. Combinations of β-Lactam Antibiotics Currently in Clinical Trials Are Efficacious in a DHP-I-Deficient Mouse Model of Tuberculosis Infection , 2015, Antimicrobial Agents and Chemotherapy.
[22] Alyaa M. Abdel-Haleem,et al. Essential Role of the ESX-5 Secretion System in Outer Membrane Permeability of Pathogenic Mycobacteria , 2015, PLoS genetics.
[23] A. Camilli,et al. Genetic Basis of Persister Tolerance to Aminoglycosides in Escherichia coli , 2015, mBio.
[24] L. Kremer,et al. β-Lactamase inhibition by avibactam in Mycobacterium abscessus. , 2014, The Journal of antimicrobial chemotherapy.
[25] A. Korkegian,et al. Mutations in the Essential Arabinosyltransferase EmbC Lead to Alterations in Mycobacterium tuberculosis Lipoarabinomannan* , 2014, The Journal of Biological Chemistry.
[26] R. Zare,et al. LprG-Mediated Surface Expression of Lipoarabinomannan Is Essential for Virulence of Mycobacterium tuberculosis , 2014, PLoS pathogens.
[27] J. Mainardi,et al. Characterization of broad-spectrum Mycobacterium abscessus class A β-lactamase. , 2014, The Journal of antimicrobial chemotherapy.
[28] B. Gicquel,et al. Mycobacterium abscessus: a new antibiotic nightmare. , 2012, The Journal of antimicrobial chemotherapy.
[29] Jay Shendure,et al. Genome-Scale Identification of Resistance Functions in Pseudomonas aeruginosa Using Tn-seq , 2011, mBio.
[30] Young Kil Park,et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. , 2009, American journal of respiratory and critical care medicine.
[31] S. Holland,et al. Pulmonary nontuberculous mycobacterial infections: antibiotic treatment and associated costs. , 2009, Respiratory medicine.
[32] W. Jacobs,et al. Lipoprotein Processing Is Essential for Resistance of Mycobacterium tuberculosis to Malachite Green , 2009, Antimicrobial Agents and Chemotherapy.
[33] K. Nash,et al. A Novel Gene, erm(41), Confers Inducible Macrolide Resistance to Clinical Isolates of Mycobacterium abscessus but Is Absent from Mycobacterium chelonae , 2009, Antimicrobial Agents and Chemotherapy.
[34] T. Parish,et al. The Critical Role of embC in Mycobacterium tuberculosis , 2008, Journal of bacteriology.
[35] J. Casanova,et al. Importance of T Cells, Gamma Interferon, and Tumor Necrosis Factor in Immune Control of the Rapid Grower Mycobacterium abscessus in C57BL/6 Mice , 2007, Infection and Immunity.
[36] N. Ampel. Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases , 2007 .
[37] G. Hatfull,et al. Recombineering in Mycobacterium tuberculosis , 2007, Nature Methods.
[38] K. Khoo,et al. The Emb proteins of mycobacteria direct arabinosylation of lipoarabinomannan and arabinogalactan via an N‐terminal recognition region and a C‐terminal synthetic region , 2003, Molecular microbiology.
[39] E. Rubin,et al. Genes required for mycobacterial growth defined by high density mutagenesis , 2003, Molecular microbiology.
[40] R. Wallace,,et al. Clinical and Taxonomic Status of Pathogenic Nonpigmented or Late-Pigmenting Rapidly Growing Mycobacteria , 2002, Clinical Microbiology Reviews.
[41] K. Khoo,et al. The Role of the embA and embB Gene Products in the Biosynthesis of the Terminal Hexaarabinofuranosyl Motif of Mycobacterium smegmatisArabinogalactan* , 2001, The Journal of Biological Chemistry.
[42] E. Rubin,et al. Comprehensive identification of conditionally essential genes in mycobacteria , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[43] A. Telenti,et al. Role of embB in natural and acquired resistance to ethambutol in mycobacteria , 1997, Antimicrobial agents and chemotherapy.
[44] L. Kremer,et al. b-Lactamase inhibition by avibactam in Mycobacterium abscessus , 2015 .